Encapsulating peritoneal sclerosis-Have we found the perpetrator?

Peritoneal Dialysis International

Volumn 29, Issue 5, 2009, Pages 499-501

  Summers, Angela M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; C REACTIVE PROTEIN; CHLORHEXIDINE GLUCONATE; MATRIX METALLOPROTEINASE; PIRFENIDONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BACTERIAL PERITONITIS; DISEASE COURSE; DISEASE MODEL; DRUG MECHANISM; ENCAPSULATING PERITONEAL SCLEROSIS; GENETIC VARIABILITY; HUMAN; NONHUMAN; PATHOGENESIS; PERITONEAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; C57BL MOUSE; FIBROSIS; GENE TRANSFER; GENETICS; MOUSE; NOTE; PATHOLOGY; PERITONEAL DIALYSIS;

ANIMALS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; HUMANS; MICE; MICE, INBRED C57BL; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 74349123865     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.1177/089686080902900504     Document Type: Article

References (14)

1. Topley N. Animal models in peritoneal dialysis: more questions than answers? Perit Dial Int 2005; 25:33-4.
2. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16:1262-6.
3. Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002; 46:505-10.
4. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995; 47:287-91.
5. Liu L, Shi CX, Ghayur A, Zhang C, Su JY, Hoff CM, et al. Prolonged peritoneal gene expression using a helperdependent adenovirus. Perit Dial Int 2009; 29:508-16.
6. Higuchi C, Tanihata Y, Nishimura H, Naito T, Sanaka T. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum. Ther Apher Dial 2005; 9:173-81.
7. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007; 22:2838-48.
8. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
9. Garosi G, Cappelletti F, Di Paolo N. Fibrosis and sclerosis: different disorders or different stages? Contrib Nephrol 2006; 150:62-9.
10. Kawanishi H. The pathogenesis and therapeutic option of encapsulating peritoneal sclerosis. Int J Artif Organs 2005; 28:150-5.
11. Yao Q, Pawlaczyk K, Ayala ER, Styszynski A, Breborowicz A, Heimburger O, et al. The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. Nephron Exp Nephrol 2008; 109:e71-8.
12. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8:93-7.
13. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007; 34:1670-3.
14. Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51:1574-80.